Helixgate

Helixgate

Uncategorized

STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection

Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agency’s main reason for rejecting the drug in January. 

Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, makers of the drug called Ebvallo, said Thursday that a meeting held in late April with FDA officials ended with the agency agreeing that their already completed, single-arm clinical trial was sufficient to support a review and potential approval. 

When the FDA rejected Ebvallo, the agency said the same study was flawed and the data produced from it was “insufficient” to support the drug’s approval. The drug’s review was conducted by the FDA’s Center for Biologics Evaluation and Research, led at the time by Vinay Prasad. He departed the agency at the end of April. 

Continue to STAT+ to read the full story…

Read More

Published

on

Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agency’s main reason for rejecting the drug in January. 

Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, makers of the drug called Ebvallo, said Thursday that a meeting held in late April with FDA officials ended with the agency agreeing that their already completed, single-arm clinical trial was sufficient to support a review and potential approval. 

When the FDA rejected Ebvallo, the agency said the same study was flawed and the data produced from it was “insufficient” to support the drug’s approval. The drug’s review was conducted by the FDA’s Center for Biologics Evaluation and Research, led at the time by Vinay Prasad. He departed the agency at the end of April. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: More political interference at the FDA?

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Published

on

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

This is a photo of a young RFK Jr. trying to ride a small rhino. Send news tips and RINO jokes to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Former DOGE co-founder v. former state Covid-19 czar

Although most people whom DOGE fired from HHS probably don’t live in Ohio, they may feel a personal connection to the gubernatorial race there.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Angelini inks $4.1B Catalyst buy to enter US rare disease market

Published

on

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Continue Reading

Uncategorized

Gilead wipes out most of Arcellx workforce

Published

on

Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.

Continue Reading
Advertisement

Trending